BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2021 Results Conference Call July 28, 2021 4:30 PM ET
Company Participants
Traci McCarty - VP, IR
J.J. Bienaimé - Chairman and CEO
Jeff Ajer - EVP and Chief Commercial Officer
Hank Fuchs - President, Worldwide Research and Development
Greg Guyer - EVP and Chief Technical Officer
Brian Mueller - EVP and CFO
Conference Call Participants
Cory Kasimov - JP Morgan
Robyn Karnauskas - Truist Securities
Salveen Richter - Goldman Sachs
Geoff Meacham - Bank of America
Debjit Chattopadhyay - Guggenheim Securities
Phil Nadeau - Cowen Company
Paul Matteis - Stifel
Gena Wang - Barclays
Joori Park - SVB Leerink
Michelle Gilson - Canaccord Genuity
Kennen MacKay - RBC Capital Markets
Matthew Harrison - Morgan Stanley
Operator
Welcome to the BioMarin Second Quarter 2021 Financial Results Conference Call. Hosting this conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.
Traci McCarty
Thank you, Grace. Thank you all for joining us today.
To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development.
Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K report.
On the call today from BioMarin management are J.J. Bienaimé, Chairman and Chief Executive Officer; Jeff Ajer, Executive Vice President, Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; Greg Guyer, Executive Vice President and Chief Technical Officer; and Brian Mueller, Executive Vice President, Chief Financial Officer.
We hope to
- Read more current BMRN analysis and news
- View all earnings call transcripts